Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), is being used increasingly in immunosuppressant therapy after solid organ transplantation (1-3). Its immunosuppressive activity is thought to reside in the inhibition of inosine monophosphate dehydrogenase (IMPDH), leading to a suppression of purine nucleotide synthesis in lymphocytes, thereby suppressing cell mitosis (3, 4) . MPA is converted in the liver mainly to the 7-O-glucuronide metabolite, mycophenolic acid glucuronide (MPAG), which does not have immunosuppressant activity (3, 5) . During MMF therapy, MPAG peak concentrations observed in plasma of patients (5-600 mg/L) can be up to 300-fold higher than those of MPA (0.1-50 mg/L). Whether drug monitoring of MPA or MPAG is required to improve the therapeutic efficacy or to minimize adverse side effects is still under investigation (3, 6) . For monitoring of MPA concentrations in human plasma, several HPLC procedures as well as one immunoassay (Emit; Behring-Syva) are available (3, 6) .
Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), is being used increasingly in immunosuppressant therapy after solid organ transplantation (1) (2) (3) . Its immunosuppressive activity is thought to reside in the inhibition of inosine monophosphate dehydrogenase (IMPDH), leading to a suppression of purine nucleotide synthesis in lymphocytes, thereby suppressing cell mitosis (3, 4) . MPA is converted in the liver mainly to the 7-O-glucuronide metabolite, mycophenolic acid glucuronide (MPAG), which does not have immunosuppressant activity (3, 5) . During MMF therapy, MPAG peak concentrations observed in plasma of patients (5-600 mg/L) can be up to 300-fold higher than those of MPA (0.1-50 mg/L). Whether drug monitoring of MPA or MPAG is required to improve the therapeutic efficacy or to minimize adverse side effects is still under investigation (3, 6) . For monitoring of MPA concentrations in human plasma, several HPLC procedures as well as one immunoassay (Emit; Behring-Syva) are available (3, 6) .
In the present investigation we addressed the question as to whether MPA and MPAG are stable in human plasma because it is possible that deglucuronidation of MPAG might take place in vitro during shipping and sample storage, thus leading to false high MPA concentrations. For this purpose, we added three different MPA and MPAG concentrations to three different pools of human plasma and followed both MPA and MPAG plasma concentrations for 7 days at three different storage temperatures. MPA and MPAG concentrations were measured using an HPLC method developed recently in our laboratory (7) .
For this study, MPA, MPAG, and the carboxy butoxy ether of MPA (MPAC) were a gift of Hoffmann-La Roche (Grenzach-Wyhlen, Germany). Sodium tungstate dihydrate, potassium dihydrogen phosphate, sodium hydroxide, phosphoric acid, and perchloric acid were from Merck. Acetonitrile (HPLC grade) was obtained from S.T. Baker B.V. Stock solutions of MPA and MPAC (1 g/L) were prepared in acetonitrile and stored at Ϫ20°C. The MPAG stock solution (5 g/L) was prepared in 800 mL/L acetonitrile-200 mL/L water and was stored in the same way.
EDTA blood from patients not undergoing MMF therapy and sent to our laboratory for routine blood cell counting was pooled, and plasma was obtained by centrifugation (3000g for 15 min). Three different plasma pools were prepared, and each pool was divided into two equal parts. MPA was added to the one set of three pools to yield the following final concentrations: 1, 10, or 50 mg/L. MPAG was added to the other set of three pools to give the following final concentrations: 50, 200, or 500 mg/L. Because the MPAG was contaminated with MPA, the plasma pools to which MPAG was added also contained MPA at concentrations of ϳ0.15, 0.6, and 1.5 mg/L, respectively. This MPA contamination has been observed before (5) and was determined chromatographically in our MPAG stock solution by the ultraviolet spectrum and retention time. The resulting six plasma pools were further split into three parts, which were stored separately at Ϫ20°C, 4°C, or at room temperature. MPA and MPAG concentrations were determined immediately after addition of the substances, and after 1 day, 3 days, and 1 week of storage. MPA was also determined at the same time intervals in the pools to which only MPA was added. In addition, 14 specimens of EDTA plasma from renal (n ϭ 9) and liver (n ϭ 5) transplant recipients undergoing MMF therapy and sent to the laboratory for routine determination of MPA were stored at room temperature. MPA concentrations were analyzed before storage and again after storage for 7 days.
MPA and MPAG were quantified according to a procedure developed recently in our laboratory (7) . Briefly, for the determination of plasma concentrations of MPAG and MPA, 200 L of plasma and 100 L of acetonitrile containing the internal standard MPAC (15 mg/L) were mixed by vortex-mixing in a 1.5-mL polypropylene tube for 5 s. This was followed by the sequential addition of 20 L of 150 g/L perchloric acid and 20 L of 250 g/L sodium tungstate. The tube was mixed by vortex-mixing for 15 s after each addition. The sample was then centrifuged for 5 min at 10 000g, and 50 L of the supernatant was removed for chromatography.
The HPLC system consisted of a chromatographic pump (M450), an automatic injector (GINA 50), a diode array detector (UVD 340S), a computer interface system controller linked to a personal computer (Gynkotek), and a 250 ϫ 4.6 mm Symmetry C 18 reversed-phase column (Waters Associates). The column was maintained at 38°C. The mobile phase consisted of solution A (250 mL/L acetonitrile-750 mL/L phosphate buffer, pH 3.0; final phosphate buffer concentration, 20 mmol/L) and solution B (700 mL/L acetonitrile-300 mL/L phosphate buffer, pH 6.5; final phosphate buffer concentration, 20 mmol/L), which formed the following gradient: 0 -4.5 min, 97% A-3% B; 5-12 min, 70% A-30% B; 12.5-14.5 min, 100% B. The flow rate was 1.2 mL/min, and the compounds were quantified at 215 nm. Calculations were made in the internal standard mode, using peak-area ratios. Calibration and quality control were performed by use of accurately weighed in-house plasma samples.
MPA and MPAG concentrations after days 1 and 3, and after 1 week at different storage conditions were compared with the initial concentrations, using the Wilcoxon test for paired samples. P Ͻ0.05 was considered significant. For regression analysis, the Spearman rank correlation was used.
Storage of plasma pools containing MPAG at concentrations (50, 200, and 500 mg/L) observed in plasma
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Clinical Chemistry 45, No. 1, 1999 specimens from patients undergoing MMF therapy produced a significant increase in apparent concentrations even after only 1 day of storage at room temperature. When the concentrations of MPA in plasma pools stored at room temperature were compared with their initial values (0.13-1.44 mg/L), the concentrations were increased to 0.15-1.65 mg/L on day 1, to 0.16 -1.78 mg/L on day 3, and to 0.18 -2.66 mg/L on day 7 (Table 1) . This corresponds to an overall mean increase at room temperature to 113.0% Ϯ 6.5% at day 1 (n ϭ 9; P Ͻ0.05), 122.5% Ϯ 13.1% at day 3 (n ϭ 9; P Ͻ0.05), and 161.3% Ϯ 24.0% (n ϭ 9; P Ͻ0.05) after 1 week in the three different plasma pools. Formation of MPA from MPAG was not observed during the 1-week storage period when plasma pools with added MPA were stored at either Ϫ20 or 4°C (Fig. 1A) .
There was a positive and significant correlation (r ϭ 0.87; n ϭ 27; P Ͻ0.05) between the MPAG concentration added to the plasma pools and the amount of MPA formed during storage at room temperature. However, whereas 0.77 mg/L MPA was formed from 500 mg/L MPAG during 1 week at room temperature in one pool, 1.29 mg/L was formed in another pool. This variability explains the relatively high SD observed in MPA values obtained from pools stored at room temperature (Fig. 1A) . This suggests that there are matrix-related effects such as the activity of glucuronidases and possibly other hydrolases in addition to a simple cleavage of MPAG. This is further supported by the results obtained from the storage of 14 specimens from patients undergoing MMF therapy for 1 week at room temperature, which caused a variable but overall significant increase (P Ͻ0.05) of MPA plasma concentrations ranging from 0.06 to 0.82 mg/L (median, 0.17 mg/L), corresponding to a median increase of 27.9% (range, 4.8 -97.7%).
A major influence on the magnitude of the error in the MPA determination will certainly be the ratio between MPAG and MPA concentrations in the plasma sample. The relative overestimation of MPA will be greater if the initial MPA concentrations are lower and the MPAG concentrations are higher. Because of the large differences between MPA and MPAG concentrations, with MPAG being up to 300-fold higher than MPA, the conversion of MPAG to MPA was not apparent when MPAG concentrations were measured. The increase in MPA at room temperature was therefore accompanied by a nonsignificant loss of MPAG (Fig. 1B) . When MPA was added at therapeutic concentrations (1, 10, or 50 mg/L) to three plasma pools that did not contain MPAG, the concentrations remained stable for 7 days at all temperatures investigated (Fig. 1C) .
These results show that storage and shipment of nonrefrigerated plasma samples containing MPAG concentrations such as those in patients undergoing MMF therapy may cause falsely increased MPA results. Plasma samples should therefore be shipped and stored refrigerated if drug monitoring of MPA is to be performed. (6, 8) .
In the conventional methods, quantification of the protein fractions is based on dye binding, whereas CZE uses ultraviolet detection at 214 nm for direct protein quantification via the peptide bonds. We asked whether intravascular agents such as radio-contrast media that absorb at 214 nm would simulate a monoclonal component on CZE.
We performed high resolution agarose electrophoresis with the Hydrasys analyzer (Sebia), using Hydragel 15 HR gels (Sebia) according to the manufacturer's instructions. The serum proteins were separated into the following fractions: prealbumin, albumin, ␣ 1 -antitrypsin, ␣ 1 -lipoprotein, haptoglobin plus ␣ 2 -macroglobulin, ␤lipoprotein, transferrin, complement C3, and the gamma globulins. Spectrophotometric analysis was done with a Varian Cary 3 biospectrophotometer (Varian). We combined sera from five adults for the addition experiments. The capillary zone and agarose electropherograms of each of the five sera were normal.
The CZE electropherograms (Beckman Paragon CZE A, overall changes in the MPA concentrations in plasma pools (n ϭ9) to which MPAG (50, 200, or 500 mg/L) was added. B, overall changes in the MPAG concentrations in plasma pools (n ϭ 9) to which MPAG (50, 200, or 500 mg/L) was added. C, overall changes (n ϭ 9) in the MPA concentrations in plasma pools to which MPA (1, 10, or 50 mg/L) was added. Data are given as percentages of initial values and are displayed as mean Ϯ SD; ‫,ء‬ P Ͻ0.05. For additional experimental details, see text.
